Agentic AI is Ready. Most Pharma Organizations Are Not

Axtria Ignite 2026 returns June 10–11 in Princeton, New Jersey, and this year’s theme is “Industrializing Intelligence: The Agentic Enterprise.”

What does that mean? Consider this: Somewhere right now, a pharma operations team is staring at an agentic AI pilot that worked and trying to explain to leadership why the next step costs three times as much. Scaling is the hard part. Axtria Ignite 2026 is built to answer that.

400+ senior life sciences executives will come together at Ignite 2026, and three questions will run through nearly every conversation:

1. How do you identify where the business impact is?
2. How do you get people and agents working together effectively?
3. How do you fund and govern agentic AI to separate the big bets from the no-regret moves?

The results are real: territory alignment compressed from weeks to minutes, launch timelines cut dramatically, and forecasting that took entire teams now run autonomously. How do you put that into a CFO-ready business case? One that defines value, measures it honestly, and holds up in enterprise deployment.

That’s where organizations are still finding their footing. And it’s what Ignite 2026 is meant to solve.

At Ignite, you’ll hear how the companies moving fastest apply a two-step discipline:

• First, they identify which business processes stand to deliver the greatest impact if agentic AI is applied; the high-volume, high-value work where speed or precision directly drives revenue or reduces cost.
• Then they determine which tasks in those processes can be scoped, measured, and handed to a dedicated agent, and then be scaled up.

Once priority areas are mapped to jobs, the conversation changes sharply: not ‘will AI replace my team?’ but 'which of these jobs should agents own, and which stay with a human?' The experts at Ignite 2026 will reveal how change management takes as much attention as the tech itself.

Then there’s the data. Agentic AI is only as good as what it sees. If the data is siloed, inconsistent, or outdated (and in most pharma organizations, it’s at least one), the output reflects that. The answer might look confident, but it’s built on shaky inputs.

Budgeting is just as complex. Some foundational moves are no-brainer investments. Others are swings for the fences that need a clear line to revenue or costs.

Axtria Ignite 2026 is built to work through all of this. Peers from leading pharma companies will be sharing the full picture: the governance, workforce, and ROI challenges.

“The reframe that changes everything is ‘Jobs-to-be-Done.’ In pharma Commercial Operations and Medical Affairs, the jobs are specific and repeatable: KOL engagement sequencing, territory rebalancing, forecast reconciliation, content personalization, etc. When you scope an agent to a defined job rather than a broad function, deployment becomes manageable, measurement becomes honest, and that ROI conversation with one’s CFO becomes much easier to have.”

— Ashish Kathuria, Client Business Unit Leader, Axtria

Axtria Ignite 2026 is by invitation only. Request your registration here.